1st - 2nd February 2020
Our platform surfaced potential drugs and through a triage process using our models, we identified Baricitinib, an approved rheumatoid arthritis drug, as a potential treatment to inhibit viral infection.
February 4th 2020
Our research was published in The Lancet and we signed the Wellcome Trust pledge to share our research in response to the emerging global health crisis.
February 28th 2020
We published a second paper examining the affinity and selectivity of all the approved drugs. This further research indicated that Baricitinib reduces endocytosis and the body’s hyperinflammatory response to the virus, thus potentially reducing patient mortality rates.
10th April 2020
Eli Lilly, who owns Baricitinib, announced an agreement with the US National Institute for Allergies and Infectious Diseases (NIAID) to enter Baricitinib into clinical trials in the US, with planned expansion to additional sites in Europe and Asia. Results are expected within the next few months.